ZGN-440 for Injectable Suspension ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
193	Prader-Willi syndrome	2

193. Prader-Willi syndrome

---

Clinical trials : 113 /  Drugs : 111 - (DrugBank : 26) / Drug target genes : 48 - Drug target pathways : 102

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02179151 (ClinicalTrials.gov)	September 2014	25/6/2014	Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome	Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Prader-Willi Syndrome to Evaluate Total Body Weight, Food-related Behavior, and Safety Over 6 Months	Prader-Willi Syndrome;Obesity	Drug: ZGN-440 for Injectable Suspension;Drug: ZGN-440 Placebo for Injectable Suspension	Zafgen, Inc.	NULL	Terminated	12 Years	65 Years	All	108	Phase 3	United States
2	NCT01818921 (ClinicalTrials.gov)	June 2013	21/3/2013	An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome	Randomized, Double-Blind, Placebo Controlled, Parallel Dose Ranging Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Over-weight and Obese Subjects With Prader-Willi Syndrome to Evaluate Weight Reduction, Food-related Behavior, Safety, and Pharmacokinetics Over 4 Weeks Followed by Optional 4-Week Open-Label Extension	Obesity;Over-weight;Prader-Willi Syndrome	Drug: ZGN-440 sterile diluent;Drug: 1.2 mg ZGN-440 for injectable suspension;Drug: 1.8 mg ZGN-440 for injectable suspension	Zafgen, Inc.	NULL	Completed	16 Years	65 Years	Both	17	Phase 2	United States